First Time Loading...

Genmab A/S
NASDAQ:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
NASDAQ:GMAB
Watchlist
Price: 26.23 USD -0.68%
Updated: Jun 14, 2024
Have any thoughts about
Genmab A/S?
Write Note

Intrinsic Value

Genmab A/S operates as an international biotechnology company. [ Read More ]

The intrinsic value of one GMAB stock under the Base Case scenario is 40.8 USD. Compared to the current market price of 26.23 USD, Genmab A/S is Undervalued by 36%.

Key Points:
GMAB Intrinsic Value
Base Case
40.8 USD
Undervaluation 36%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Genmab A/S

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling GMAB stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Genmab A/S

Current Assets 34.4B
Cash & Short-Term Investments 29.6B
Receivables 4.7B
Other Current Assets 106m
Non-Current Assets 2.3B
Long-Term Investments 153m
PP&E 1.9B
Intangibles 23m
Other Non-Current Assets 275m
Current Liabilities 2.8B
Other Current Liabilities 2.8B
Non-Current Liabilities 1.4B
Long-Term Debt 918m
Other Non-Current Liabilities 506m
Efficiency

Earnings Waterfall
Genmab A/S

Revenue
17.8B DKK
Cost of Revenue
-4.6B DKK
Gross Profit
13.2B DKK
Operating Expenses
-7.5B DKK
Operating Income
5.7B DKK
Other Expenses
-234m DKK
Net Income
5.5B DKK

Free Cash Flow Analysis
Genmab A/S

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

GMAB Profitability Score
Profitability Due Diligence

Genmab A/S's profitability score is 73/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Positive Free Cash Flow
Exceptional ROIC
Positive Operating Income
73/100
Profitability
Score

Genmab A/S's profitability score is 73/100. The higher the profitability score, the more profitable the company is.

GMAB Solvency Score
Solvency Due Diligence

Genmab A/S's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
99/100
Solvency
Score

Genmab A/S's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GMAB Price Targets Summary
Genmab A/S

Wall Street analysts forecast GMAB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GMAB is 137.98 USD with a low forecast of 23.16 USD and a high forecast of 479.5 USD.

Lowest
Price Target
23.16 USD
12% Downside
Average
Price Target
137.98 USD
426% Upside
Highest
Price Target
479.5 USD
1 728% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

GMAB Price
Genmab A/S

1M 1M
-10%
6M 6M
-15%
1Y 1Y
-31%
3Y 3Y
-32%
5Y 5Y
+55%
10Y 10Y
+736%
Annual Price Range
1 830.5
52w Low
1 824
52w High
2 787
Price Metrics
Average Annual Return 28.34%
Standard Deviation of Annual Returns 27.47%
Max Drawdown -45%
Shares Statistics
Market Capitalization 119.9B DKK
Shares Outstanding 65 841 800
Percentage of Shares Shorted
N/A

GMAB Return Decomposition
Main factors of price return

What is price return decomposition?

GMAB News

Last Important Events
Genmab A/S

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Genmab A/S

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Genmab A/S Logo
Genmab A/S

Country

Denmark

Industry

Biotechnology

Market Cap

119.9B DKK

Dividend Yield

0%

Description

Genmab A/S operates as an international biotechnology company. The company specializes in the creation and development of antibody therapeutics for the treatment of cancer. The firm is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Contact

KOEBENHAVN V
Kalvebod Brygge 43
+4570202728.0
https://www.genmab.com/

IPO

2000-10-01

Employees

1 212

Officers

Co-Founder, President & CEO
Dr. Jan G.J. van de Winkel Ph.D.
Executive VP & CFO
Mr. Anthony Pagano
Executive VP & Chief Legal Officer
Ms. Birgitte Stephensen M.Sc.
Executive VP & Chief Strategy Officer
Dr. Martine J. van Vugt Ph.D.
Senior Director of Clinical Operations & Non-Independent Director
Mr. Martin Schultz
Executive VP, Chief Medical Officer & Head of Experimental Medicines
Dr. Tahamtan Ahmadi
Show More
Senior Director, Head of Antibody Research Materials & Non-Independent Director
Dr. Mijke Zachariasse Ph.D.
Senior Director of Finance Japan & Non-Independent Director
Mr. Takahiro Hamatani
Executive VP & COO
Mr. Anthony Mancini
Senior Director, VP & Head of Investor Relations
Mr. Andrew Carlsen
Show Less

See Also

Discover More
What is the Intrinsic Value of one GMAB stock?

The intrinsic value of one GMAB stock under the Base Case scenario is 40.8 USD.

Is GMAB stock undervalued or overvalued?

Compared to the current market price of 26.23 USD, Genmab A/S is Undervalued by 36%.